相关实验视频
Updated: May 10, 2025
08:36
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
924
阿巴塞普特用于治疗肌肉炎相关的间歇性肺病 (ATtackMy-ILD)
Rohit Aggarwal1, Nantakarn Pongtarakulpanit1,2, Daniel I Sullivan3
1Department of Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, United States of America.
Rheumatology (Oxford, England)
|April 24, 2025
概括
在24周的抗合成酶综合征相关的间歇性肺病中,阿巴cept没有显著改善肺功能. 然而,长期使用显示出有前途的趋势,这表明需要进一步研究.
科学领域:
- 风湿病学和肺病学 风湿病学和肺病学
- 免疫学 免疫学 免疫学
- 临床试验 临床试验
背景情况:
- 与抗合成酶综合征相关的间歇性肺病 (ASyS-ILD) 是一种严重的疾病,治疗选择有限.
- 作为T细胞协同刺激调节剂的阿巴cept在其他自身免疫性疾病中表现出潜力.
研究的目的:
- 评估阿巴特切普特在患有活性ASyS-ILD的患者中的疗效和安全性.
- 评估48周内阿巴塔塞普特对肺功能和疾病活性的影响.
主要方法:
- 这是一项为期24周的随机化,安慰剂控制的试验试验,涉及20名活跃ASyS-ILD的患者.
- 主要终点:预测强迫生命能力 (%FVC) 的变化. 二级终点包括%DLCO,呼吸短促和肺部疾病活动.
- 然后对所有参与者进行24周的开放式延长治疗.
主要成果:
- 在24周内,在阿塔巴塞普和安慰剂之间,FVC%变化没有显著差异.
- 在48周观察到有利于阿巴切的%FVC,FVC (毫升),%DLCO和呼吸短促的趋势,没有统计学意义.
- 在阿巴切手臂中,肺病活动视觉模拟量表 (VAS) 和定量图像分析 (QIA) 评分的显著改善.
结论:
- 阿巴塞普在24周后没有显示FVC%的显著改善.
- 在48周的趋势表明潜在的好处,保证更大的,长期的随机对照试验.
- 在这个患者群体中,阿巴塔塞普特的耐受性一般很好.
相关概念视频
01:20Myasthenia Gravis: Overview and Treatment
958
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
958
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
101
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
101
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
97
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
97
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
86
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
86
01:29Drugs for Treatment of Ulcerative Colitis in IBD
102
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
102
01:29Inflammatory Bowel Disease IV: Pharmacological Management
80
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
80